In a three-way crossover trial, six healthy Finnish-Merino-Awassi ewes were given a single intravenous injection of norfloxacin nicotinate (in a dose equivalent to 25 mg of norfloxacin base per kg of body weight) during nursing, 1 day after weaning, and 1 month after weaning. Blood and milk samples were collected at different time intervals following dosing, and norfloxacin concentrations were determined by a highperformance liquid chromatography assay. The serum drug concentration versus time data were analyzed by a noncompartmental approach which was based on the statistical-moment theory. The (Fig. 1) , a characteristic which improves dramatically norfloxacin water solubility, and thus, unlike norfloxacin base, the nicotinate derivative can be used for parenteral administration. In the body the compound is instantly dissociated into norfloxacin and nicotinic acid. Therefore, the drug acts in the body as norfloxacin. The dose consists of 30% of nicotinic acid, which at a high dose of 25 mg/kg of body weight represents 10 to 25% of the recommended therapeutic daily dose (4).
ml/min/kg (injection 1 month after weaning). The mean residence times were 335 + 83, 797 + 129, and 481 ± 102 min and terminal half-lives were 266 + 51, 603 ± 94, and 372 ± 68 min for the respective treatments. The estimated volumes of distribution at steady state were 1.3 ± 0.1, 1.2 ± 0.1, and 1.4 ± 0.2 liter/kg for the respective treatments. Milk norfloxacin concentrations were up to 40 times higher than the corresponding concentrations in serum during lactation. Accordingly, in ewes with 1.5 liter of milk in the udder more than half of the drug in the animal appeared to be in the milk Therapeutic concentrations of norfloxacin could be detected in the sera of suckling lambs, implicating that fluoroquinolone therapy should be discouraged during breast feeding. In lactating ewes and in ewes with full udders, moment analysis calculations did not show a significant difference between the system moment mean residence time and the system matrix mean residence time values. Thus, the pharmacokinetics of norfloxacin in the three groups could be described by the classical two-compartment open-body model with input and output occurring from the central compartment. The results did not support the existence of a distinguishable milk compartment. Milk secretion seemed to act as one of the clearance processes of the drug when milk was continuously removed.
Norfloxacin [1-ethyl-6 -fluoro-1,4-dihydro-4-oxo-7-(1-piperazinyl)-3-quinolinecarboxylic acid] is a broad-spectrum antimicrobial fluoroquinolone. The (Fig. 1) , a characteristic which improves dramatically norfloxacin water solubility, and thus, unlike norfloxacin base, the nicotinate derivative can be used for parenteral administration. In the body the compound is instantly dissociated into norfloxacin and nicotinic acid. Therefore, the drug acts in the body as norfloxacin. The dose consists of 30% of nicotinic acid, which at a high dose of 25 mg/kg of body weight represents 10 to 25% of the recommended therapeutic daily dose (4).
Recent reports indicated that pharmacokinetics of antibiotics may change in lactating animals (9, 10) . These changes in drug disposition were demonstrated for benzylpenicillin in ewes and marbofloxacin in sows. Despite the difference in chemical structure and pharmacokinetics of these antibiotics, the effects of lactation on drug clearance were similar. Especially in human therapeutics, the milk/plasma drug concentra-tion ratio is often unknown, and safety considerations during maternal drug intake lead to cessation of breast feeding. Atkinson 6 .0. The flow rate was set at 0.7 ml/min. The detector wavelength was adjusted to 277 nm. The detection limit was 0.07 mg/liter. Precision analysis showed interday coefficients of variation of 9.7% at 0.1 ,ug/ml, 7.1% at 1.0 ,ug/ml, and 2.2% at 100 ,ug/ml among six replicates.
The correlation coefficient of linearity of the method over the concentration range from 0.1 to 100 ,ug/ml was 0.9931, and the recovery from serum and milk was >85%.
The assay procedure was as follows. (0) in a three-way crossover design study.
like the samples. Sample norfloxacin concentrations were determined by use of standard curves.
The pharmacokinetics of norfloxacin were analyzed by a noncompartmental approach based on the statistical-moment theory (13, 14) . The linear terminal-elimination slope (,3) was calculated by linear least-squares regression analysis using the last four to six serum drug concentration versus time points.
The terminal half-life (tl2) was calculated as ln 2/I. The system moment mean residence time [MRT(S,MO)] was determined as AUMC/AUC, where AUC is the area under the concentration-time curve from time zero to infinity (AUCO,) and AUMC is the area under the product of time and the serum drug concentration versus time from time zero to infinity (14) . The AUC and AUMC were calculated by the trapezoidal method with extrapolation of infinity.
The system matrix mean residence time [MRT(S,MA)] was determined by fitting a two-compartment model to the data by use of a computer program based on a weighted, iterative, nonlinear least-squares regression analysis (13): at + ,3 -kj,}(a x 3), where a is the distribution slope and klo is the elimination rate constant from the central compartment (11) .
The volume of distribution at steady state (Vss) was calculated as D x MRT/AUC, where D is the dose (3).
Total body clearance (CL) was calculated as D/AUC (5).
A two-way analysis of variance and the Newman-Keuls test were used for determining statistical differences between the calculated pharmacokinetics values, and P < 0.05 was considered significant.
RESULTS
The mean serum norfloxacin concentrations are depicted in Fig. 2 . The mean pharmacokinetic parameters of norfloxacin for the three treatments are presented in Tables 1 and 2 . The mean milk norfloxacin concentrations for phase I treatment are given in Table 3 . The clearance in the ewes 1 day after weaning was significantly lower than clearances in the two other groups. The t112 and MRT of norfloxacin following intravenous administration were significantly different from those for the two other treatment groups. The Vss for the three study groups did not differ significantly. The total milk amount in the udder was 1.5 ± 0.5 liter 48 h after weaning, and the mean milk norfloxacin concentration was 91 ± 9 ,ug/ml. Serum VOL. 38, 1994 In phase I animals, t112 and MRT were significantly shorter than those in phase III animals. This is in accordance with Petracca et al. (10) reporting that the t112 of marbofloxacin was significantly shorter in lactating sows. The results showed that the milk/serum norfloxacin concentration ratio reached a peak (40:1) at 240 min following dosing and decreased to 30:1 at 1,440 min after drug administration. In phase I animals, despite the high concentration in milk, comparable to that for phase II animals, drug elimination in phase I animals was slightly faster than that in phase III animals. Obviously, the continuous emptying of the udder by suckling resulted in the largest CL value or increased drug elimination from the system. As a result of large amounts of the drug excreted in the milk, the suckling lambs were subjected to oral norfloxacin administration. Assuming a mean milk production rate of 100 ml/h, totally consumed by a lamb weighing 5 kg, and given the milk concentrations in Table 3 , the cumulative amount of norfloxacin ingested by the suckling lamb could reach 250 mg. The serum norfloxacin concentrations in the lambs 4 and 6 h following dosing of their mothers were above the MICs for a number of pathogens and, therefore, potentially therapeutically efficacious. The milk/plasma drug concentration ratio observed in the present study was at least five times higher than could be predicted by Atkinson and Begg (1) . Therefore, mechanisms other than the effect of pKa, octanol-water partition, and protein binding were apparently involved in norfloxacin distribution to milk. The quantitative and qualitative differences in weight, milk production, milk composition, and infant weight between lactating ewes and humans are minor. Therefore, norfloxacin and possibly other fluoroquinolone treatment of breast-feeding women should be discouraged until data for humans have been generated. In phase II, 9% of the given dose was found in the milk 24 h after administration. The amount of the drug in the body equals the product of the concentration in serum and V. As the milk/serum norfloxacin concentration ratio was 30:1, it appears that more than half of the norfloxacin amount in the animal was concentrated in the milk, which represents only 2.3% of mean total body weight. The precise contribution of this phenomenon to the pharmacokinetics of norfloxacin in the animal could not be analyzed without specific data on renal CL. Surprisingly, the extremely large amount of the drug in milk did not have any effect on V. Oukessou et al. (9) reported a significant increase of Vss lactating ewes following administration of benzylpenicillin, an antibiotic which has a low V in nonlactating animals.
The milk/plasma drug concentration ratio has been described as a function of the pharmacokinetic model that best describes maternal drug distribution and elimination (12) . In these modellings an additional milk compartment played a central role. The MRT and Vss are exit-site-dependent parameters (8) . The milk in the mammary gland at any given time may be considered a peripheral compartment, particularly when a considerable amount of the drug can be found in the milk. It has been reported that if the elimination is from a (peripheral) compartment other than the central compartment, the MRT(S,MO) and MRT(S,MA) would not be equal (11) . According to the results for phase I animals in the present study both MRT values were similar, indicating that the drug elimination through the milk is part of total body CL rather than peripheral compartment elimination. According to the serum drug concentration-time curves for phase I and II animals, there was no indication of an additional, milk, compartment. Therefore, the present study does not support the assumption that the fit of a certain compartmental model for lactating subjects differs from that for nonlactating subjects.
